Allogeneic peripheral blood progenitor cell transplantation: the Taiwan experience

Tzeng, Cheng‐Hwai; Lin, Jeong‐Shi; Chen, Po‐Min; Hu, Hui‐Yu; Lyou, Jau‐Yi; Chen, Ying‐Ru

doi:10.1046/j.1537-2995.1997.37297203535.x

Cited by 2 publications

(2 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent reports on HSCT from Asian countries suggest the progress of HSCT in this region. [5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21] However, no comprehensive picture of the current state of HSCT in Asia has been obtained. The Asia-Pacific region consists of countries with various ethnic, economical and social backgrounds.…”

Section: Introductionmentioning

confidence: 99%

Hematopoietic SCT activity in Asia: a report from the Asia-Pacific Blood and Marrow Transplantation Group

Yoshimi

Suzuki

Atsuta

et al. 2010

Bone Marrow Transplant

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Hematopoietic SCT activity in Asia: a report from the Asia-Pacific Blood and Marrow Transplantation Group

Yoshimi

Suzuki

Atsuta

et al. 2010

Bone Marrow Transplant

View full text Add to dashboard Cite

“…In Taiwan, using PBSC as the graft had been started earlier in the mid-1990s. 7 Along with the increasing number of cases using PBSC grafts from matched-related donors, the long-term safety of allogeneic PBSCT was established. Finally, the allogeneic PBSCT was applicable from unrelated donors registering in the Tzu Chi Bone Marrow Donor Registry (TCBMDR) after a long debate in Taiwan (see below).…”

Section: Transplantation Centers and Activitiesmentioning

confidence: 99%

Current status of hematopoietic stem cell transplantation in Taiwan

Hsiao

Chen

et al. 2008

Bone Marrow Transplant

View full text Add to dashboard Cite

In Taiwan, hematopoietic SCT (HSCT) has been used to treat patients with hematological diseases since 1983. Since then, more than 2200 patients have undergone HSCT in 15 large hospitals. The disease entities included acute leukemia in 37% of cases, non-Hodgkin's lymphoma in 26%, CML in 10%, multiple myeloma in 7% and severe aplastic anemia in 6%. The conditioning regimens used were mainly myeloablative (84% of cases). Nonmyeloablative regimens were fludarabine-based. The average age of allogeneic recipients was at least 10 years older than those in the era before their application. The grafts of all patients were derived from peripheral blood in 85% of cases, BM in 13% and cord blood (CB) in 2%. Forty percent of HSCT patients received autologous grafts, whereas more than 25% of allogeneic HSCT patients received grafts from unrelated donors, and overall, there were more than 200 Taiwan HSCT recipients. Currently, CB has been used successfully in pediatric patients with thalassemia major and also in adult patients with hematological malignancy. After transplantation, there was a relatively lower prevalence of acute GVHD. However, a relatively higher proportion of hepatitis B carriers in the recipients had led to a higher incidence of viral reactivation and clinical hepatitis, which was dramatically decreased following lamivudine prophylaxis. In conclusion, HSCT has been successfully adapted to routine clinical care in Taiwan. Several important findings contributing to the progress of HSCT in the past two decades have also been noticed on this island.

show abstract

Allogeneic peripheral blood progenitor cell transplantation: the Taiwan experience

Cited by 2 publications

References 7 publications

Hematopoietic SCT activity in Asia: a report from the Asia-Pacific Blood and Marrow Transplantation Group

Hematopoietic SCT activity in Asia: a report from the Asia-Pacific Blood and Marrow Transplantation Group

Current status of hematopoietic stem cell transplantation in Taiwan

Contact Info

Product

Resources

About